Jan 21, 2011
European experts have recommended that regulators give the green light to Gilenya, paving the way to an EU-wide licence.
Swiss-based pharmaceutical company Novartis, which manufactures the drug, said a licence allowing Gilenya to be marketed in the UK was expected “in the next few months”.
The drug, already sold in the US and Russia, provides the first daily pill alternative to injected MS treatments.
The Committee for Medicinal Products for Human Use (CHMP), made up of experts from the European Medicines Agency (EMA), on Friday recommended that the EU regulator approve the drug.
***************************************************************
If you find our information worthy,
then please donate by clicking here
****************************************************************
“Providing You with ‘MS Views and News’, is what we do“
.
REMAIN up–to–date with educational information of
Multiple Sclerosis when registered at
the MS Views and News website.
.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews